ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,621 to 2,640 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Betamethasone vs Placebo: Number of Neonates With Hypoglycemia343 of 1,427

210 of 1,400

9.0 points

6.1 to 11.9

2,827NCT01222247

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Betamethasone vs Placebo: Number of Neonates With Transient Tachypnea of the Newborn95 of 1,427

138 of 1,400

-3.2 points

-5.2 to -1.2

2,827NCT01222247

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Betamethasone vs Placebo: Neonatal Outcome Composite198 of 1,427

249 of 1,400

-3.9 points

-6.6 to -1.2

2,827NCT01222247

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Betamethasone vs Placebo: Number of Neonates With Respiratory Distress Syndrome79 of 1,427

89 of 1,400

-0.8 points

-2.6 to 0.9

2,827NCT01222247

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Betamethasone vs Placebo: Neonatal Death After 72 Hours of Delivery2 of 1,427

0 of 1,400

0.1 points

-0.2 to 0.5

2,827NCT01222247

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Betamethasone vs Placebo: Number of Infants withChronic Lung Disease / Bronchopulmonary Dysplasia (BPD) Requiring Supplemental Oxygen2 of 1,427

9 of 1,400

-0.5 points

-1.1 to -0.0

2,827NCT01222247

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Betamethasone vs Placebo: Neonatal Hyperbilirubinemia167 of 1,427

140 of 1,400

1.7 points

-0.6 to 4.0

2,827NCT01222247

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Counselor vs Provider: Test Acceptance Rate1,382 of 1,959

643 of 861

-4.1 points

-7.6 to -0.5

2,820NCT00502944

Two Approaches to Routine HIV Testing in a Hospital Emergency Department

Erythropoiesis Stimulating Agents vs Methoxy Polyethylene Glycol-Epoetin Beta: deaths from any cause557 of 1,409

558 of 1,409

-0.1 points

-3.7 to 3.5

2,818NCT00773513

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)

Erythropoiesis Stimulating Agents vs Methoxy Polyethylene Glycol-Epoetin Beta: serious adverse events1,123 of 1,409

1,097 of 1,409

1.8 points

-1.2 to 4.9

2,818NCT00773513

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)

Neratinib vs Placebo: serious adverse events103 of 1,408

85 of 1,408

1.3 points

-0.6 to 3.1

2,816NCT00878709

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Intensive Blood-Pressure Lowering vs Guideline-Recommended Blood-Pressure Lowering: Death at 90 Days166 of 1,394

170 of 1,421

-0.1 points

-2.5 to 2.3

2,815NCT00716079

The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial

Betamethasone vs Placebo: Neonates Needing Immediate Resuscitation After Birth206 of 1,422

260 of 1,390

-4.2 points

-7.0 to -1.5

2,812NCT01222247

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Arm I (Aspirin) vs Arm II (Placebo): serious adverse events99 of 1,393

91 of 1,415

0.7 points

-1.2 to 2.6

2,808NCT02927249

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

Benlysta vs Non-Benlysta: deaths from any cause48 of 1,924

29 of 881

-0.8 points

-2.3 to 0.5

2,805NCT01729455

Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry

Benlysta vs Non-Benlysta: serious adverse events248 of 1,924

108 of 881

0.6 points

-2.1 to 3.2

2,805NCT01729455

Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry

FF/VI 100 mcg/25 mcg vs Usual Care: Time to an Event of Discontinuation of Initial Therapy Occurring in a Year374 of 1,396

219 of 1,403

11.2 points

8.2 to 14.2

2,799NCT01551758

A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)

FF/VI 100 mcg/25 mcg vs Usual Care: Time to the First Serious Adverse Event of Pneumonia Occuring in a Year89 of 1,396

80 of 1,403

0.7 points

-1.1 to 2.5

2,799NCT01551758

A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)

FF/VI 100 mcg/25 mcg vs Usual Care: Number of Participants With Non-serious Adverse Drug Reactions (ADR)192 of 1,396

88 of 1,403

7.5 points

5.3 to 9.7

2,799NCT01551758

A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)

FF/VI 100 mcg/25 mcg vs Usual Care: Time to First Moderate/Severe Exacerbations on Initial Therapy Occurring in a Year852 of 1,396

943 of 1,403

-6.2 points

-9.7 to -2.6

2,799NCT01551758

A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=132"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=132

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01222247-bcdd4e8c",
        "title": "Betamethasone vs Placebo: Number of Neonates With Hypoglycemia",
        "summary": "343 of 1427 against 210 of 1400; risk difference 9.0 points, 95% interval 6.1 to 11.9; NCT01222247, Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial",
        "record": "/library/comparisons/NCT01222247-bcdd4e8c",
        "nct_id": "NCT01222247",
        "kind": "outcome",
        "participants": 2827,
        "risk_difference": {
          "value": 0.09036440084092504,
          "lower": 0.06126376060509434,
          "upper": 0.11929466822040527
        },
        "group_1": "343 of 1,427",
        "group_2": "210 of 1,400",
        "difference": "9.0 points",
        "interval": "6.1 to 11.9",
        "trial_title": "Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial"
      },
      {
        "id": "NCT01222247-c45a693f",
        "title": "Betamethasone vs Placebo: Number of Neonates With Transient Tachypnea of the Newborn",
        "summary": "95 of 1427 against 138 of 1400; risk difference -3.2 points, 95% interval -5.2 to -1.2; NCT01222247, Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial",
        "record": "/library/comparisons/NCT01222247-c45a693f",
        "nct_id": "NCT01222247",
        "kind": "outcome",
        "participants": 2827,
        "risk_difference": {
          "value": -0.0319981980178196,
          "lower": -0.052473972845713895,
          "upper": -0.01172659273487213
        },
        "group_1": "95 of 1,427",
        "group_2": "138 of 1,400",
        "difference": "-3.2 points",
        "interval": "-5.2 to -1.2",
        "trial_title": "Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=133",
  "request_id": "hJNc4V_Qb_YIncQ8"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?